Monopar Therapeutics Inc.
MNPR
$60.63
$0.020.03%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -48.31% | 52.40% | -163.56% | -43.04% | -59.94% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -27.70% | -91.96% | 452.08% | 282.63% | 275.87% |
| Change in Net Operating Assets | 88.90% | -64.85% | 682.02% | 132.65% | -1,146.40% |
| Cash from Operations | 38.66% | -68.64% | -94.74% | 35.75% | -242.11% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,613.81% | -333.72% | -315.68% | 49,570.83% | 66.87% |
| Cash from Investing | -1,613.81% | -333.72% | -315.68% | 49,570.83% | 66.87% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | 4,600.00% | -99.52% |
| Repurchase of Common Stock | -52.71% | -475.04% | -214,333.33% | -3,116.00% | -1,125.23% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -73.03% | -100.69% | 560,049.09% | -3,100.00% | -103.64% |
| Foreign Exchange rate Adjustments | -31,500.00% | 2,718.42% | -91.11% | -273.33% | 94.12% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -52.16% | -265.45% | 88,452.10% | 87.59% | -1,227.41% |